Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126733 · ClinicalTrials.gov registry record · Phase 2
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
A Phase 2 study of Colorectal Cancer, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 15
- Study locations
NCT04126733 is a Phase 2 study of Colorectal Cancer that has completed, run by Bayer. The registered enrollment target is 70 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT04126733, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Nivolumab is an immunotherapy drug encouraging the body's own immune system to attack cancer cells. Both drugs have been approved, but not for how they are being used as combination therapy in this study. Brand name of regorafenib is Stivarga; brand name of nivolumab is Opdivo.
Conditions Studied
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
- BIOLOGICAL Nivolumab (Opdivo)
Study Locations (15)
Texas
- Texas Oncology-Arlington North - Arlington
- Baylor Charles A. Sammons Cancer Center at Dallas - Dallas
- University of Texas MD Anderson Cancer Center - Houston
- Texas Oncology-Sherman - Sherman
California
- City of Hope National Medical Center - Duarte
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- Miami Cancer Institute at Baptist Health South Florida - Miami
Illinois
- Illinois Cancer Specialists - Arlington Heights
Minnesota
- Minnesota Oncology Hematology, PA - Minneapolis
Nebraska
- Nebraska Cancer Specialists - Papillion
New York
- New York Oncology Hematology. P.C. - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04126733
The ClinicalTrials.gov registry entry for NCT04126733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT04126733 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04126733 about?
NCT04126733 is a clinical study titled "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)". The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether i...
What is the current status of trial NCT04126733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2019-10-14. Estimated completion is 2022-03-28.
What conditions does trial NCT04126733 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT04126733?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG), Nivolumab (Opdivo) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04126733?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04126733 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.